» Articles » PMID: 15194680

Histone Deacetylase Activity is Required to Recruit RNA Polymerase II to the Promoters of Selected Interferon-stimulated Early Response Genes

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2004 Jun 15
PMID 15194680
Citations 57
Authors
Affiliations
Soon will be listed here.
Abstract

Posttranslational modification of histones by acetylation, methylation or phosphorylation has emerged as a major mechanism to modify chromatin structure and gene expression. In most cases, transcriptionally active genes display enhanced binding of acetylated histones in their promoters. Activation of histone acetyltransferases or inhibition of histone deacetylases (HDACs) allows chromatin to assume a more open state permitting transcriptional activators to form a preinitiation complex. To our surprise, treatment of cells with the HDAC inhibitor, trichostatin A (TSA), inhibits selected interferon beta (IFNbeta)-stimulated immediate early genes that are activated by the transcription factors Stat1 and Stat2. However, IFNbeta activation of IRF-1, which requires tyrosine-phosphorylated Stat1 homodimers binding to a gamma interferon activation sequence in its promoter is not affected by TSA. Exposure of cells to TSA does not alter tyrosine phosphorylation of Stat1 or Stat2. TSA treatment of cells also does not alter the binding of Stat 1 or Stat2 to the endogenous ISG54 promoter. However, IFNbeta-stimulated binding of RNA polymerase II to the ISG54 promoter is prevented by TSA. Interestingly, ectopic expression of IRF9 reverses the inhibitory actions of TSA, suggesting that IRF9 functions to recruit RNA polymerase II to the promoter of interferon-stimulated genes. This particular function of IRF9 requires the activity of histone deacetylases.

Citing Articles

Histone deacetylases maintain expression of the pluripotent gene network via recruitment of RNA polymerase II to coding and noncoding loci.

Kelly R, Stengel K, Chandru A, Johnson L, Hiebert S, Cowley S Genome Res. 2024; 34(1):34-46.

PMID: 38290976 PMC: 10903948. DOI: 10.1101/gr.278050.123.


HDAC Inhibition as Potential Therapeutic Strategy to Restore the Deregulated Immune Response in Severe COVID-19.

Ripamonti C, Spadotto V, Pozzi P, Stevenazzi A, Vergani B, Marchini M Front Immunol. 2022; 13:841716.

PMID: 35592335 PMC: 9111747. DOI: 10.3389/fimmu.2022.841716.


Butyrate Prevents Induction of CXCL10 and Non-Canonical IRF9 Expression by Activated Human Intestinal Epithelial Cells via HDAC Inhibition.

Korsten S, Peracic L, van Groeningen L, Diks M, Vromans H, Garssen J Int J Mol Sci. 2022; 23(7).

PMID: 35409339 PMC: 8999521. DOI: 10.3390/ijms23073980.


Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia.

Tavakoli Shirazi P, Eadie L, Heatley S, Page E, Francois M, Hughes T Cancer Gene Ther. 2022; 29(8-9):1140-1152.

PMID: 35022522 DOI: 10.1038/s41417-021-00421-6.


Expression of HDACs 1, 3 and 8 Is Upregulated in the Presence of Infiltrating Lymphocytes in Uveal Melanoma.

Souri Z, Jochemsen A, Wierenga A, Kroes W, Verdijk R, van der Velden P Cancers (Basel). 2021; 13(16).

PMID: 34439300 PMC: 8393956. DOI: 10.3390/cancers13164146.